Israel starts human trials for coronavirus vaccine; schools reopen

Eighty volunteers will initially take part in the trial that will be expanded to 960 people in December. Should those trials succeed a third stage with 30,000 volunteers is scheduled for April/May

Coronavirus, vaccine, covid, drugs, clinical trials
"We are in the final stretch," said Shmuel Shapira, Director General of the Israel Institute for Biological Research
Reuters
2 min read Last Updated : Nov 01 2020 | 11:14 PM IST
Israel began human trials on Sunday for its Covid-19 vaccine candidate which, if successful, could be ready for the general public by the end of next summer.
 
Eighty volunteers will initially take part in the trial that will be expanded to 960 people in December. Should those trials succeed a third stage with 30,000 volunteers is scheduled for April/May.
 
"We are in the final stretch," said Shmuel Shapira, Director General of the Israel Institute for Biological Research.
 
The institute, which is overseen by the Defense Ministry, began animal trials for its "BriLife" vaccine in March and announced a week ago it had received regulatory approval to take it to the next stage.
 
For a factbox on the many vaccine candidates in human trials worldwide, please click onShmuel Yitzhaki, head of the institute's biology division, told Reuters that if all goes well the vaccine could reach the general population by the end of next summer.

While the first batch of volunteers received the potential vaccine, around the country elementary students returned to school as a second nationwide lockdown comes to a gradual end.
 
Restrictions in Israel, with a population of 9 million, are being slowly lifted following a steady decline in the rate of daily infections.
First through fourth graders were the first to return to school on Sunday. Older kids are still learning from home.
 
The government also approved the reopening in stages of businesses and recreational activities.
 
The country reported 674 new cases on Friday - down from a peak of more than 9,000 several weeks ago. It has reported 2,541 deaths from the pandemic.
 

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :israelCoronavirus Vaccine

Next Story